Fri, March 17, 2023
Thu, March 16, 2023
Wed, March 15, 2023
Tue, March 14, 2023
Mon, March 13, 2023
Fri, March 10, 2023
Thu, March 9, 2023

Neena Bitritto-Garg Maintained (ACAD) at Hold with Increased Target to $21 on, Mar 14th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-increased-target-to-21-on-mar-14th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Neena Bitritto-Garg of Citigroup, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $19 to $21 on, Mar 14th, 2023.

Neena has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 4 agree with Neena's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Uy Ear of "Mizuho" Reiterated at Hold and Held Target at $19 on, Monday, March 13th, 2023
  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $20 on, Wednesday, March 1st, 2023
  • Jason West of "JMP Securities" Maintained at Hold with Decreased Target to $22 on, Tuesday, February 28th, 2023
  • Tessa Romero of "JP Morgan" Maintained at Hold with Decreased Target to $17 on, Monday, November 14th, 2022


This is the rating of the analyst that currently disagrees with Neena


  • Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $22 on, Tuesday, January 3rd, 2023

Publication Contributing Sources